WHO ICTRP trial
A Phase II Clinical Trial in Patients with BRCA defective Tumours
EUCTR2009-016846-16-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-016846-16-GB |
|---|---|
| Public title | A Phase II Clinical Trial in Patients with BRCA defective Tumours |
| Scientific title | Phase II Clinical Trial of 6-Mercaptopurine(6MP)and low-dose Methotrexate In Patients With Known BRCA Defective Tumours. - A Phase II Clinical Trial in Patients with BRCA defective Tumours |
| Primary sponsor | University of Oxford |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United Kingdom |
| Conditions | Advanced or metastatic breast or ovarian cancer. MedDRA version: 16.1 Level: LLT Classification code 10028985 Term: Neoplasm breast System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA… |
| Interventions | Trade Name: Puri-Nethol Product Name: 6 Mercaptopurine Pharmaceutical Form: Tablet INN or Proposed INN: 6 Mercaptopurine CAS Number: 50-44-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name… |
| Registration date | Nov 25, 2010 |
| Target size | 65 |
| Secondary IDs | OCTO-16;ISRCTN63150635;NCT01432145 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: